IM8N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Commercial Launch MomentumA rapid, high-volume launch with accelerating new patient starts and materially upgraded full-year guidance demonstrates durable commercial adoption and prescriber penetration. Sustained quarterly starts and strong launch metrics indicate lasting revenue base potential as the product moves from early uptake to steady-state sales.
High And Improving Gross MarginsVery high and improving product gross margins reflect favorable product economics and improving gross-to-net dynamics. Durable margin strength provides operating leverage as revenue scales, improving the company’s ability to fund R&D and SG&A without proportional margin erosion over the medium term.
Stronger Balance Sheet And Cash RunwayMaterial deleveraging and a sizeable cash position reduce solvency risk and extend runway to execute launches and Phase III programs. Lower net debt and positive equity provide strategic flexibility to invest in commercialization and trials while targeting cash‑flow positivity without near‑term capital raises.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowLarge negative operating and free cash flows create persistent runway pressure despite current cash balances. Continued high cash burn from launches and Phase III programs risks requiring additional financing or cutbacks if commercial uptake or reimbursement outcomes slow, making sustainability conditional on execution.
Deep Ongoing Operating LossesEven with accelerating revenue, operating and net losses are severe enough to keep returns strongly negative. Achieving durable profitability requires sustained scale, controlled SG&A/R&D growth, and preservation of gross margins; failure on any front prolongs cash consumption and delays breakeven.
Reimbursement And Execution RiskRevenue outlook depends on favorable payer access, regulatory approvals, and stable GTN trends. European payer constraints, potential GTN increases, milestone obligations, and optimistic uptake assumptions create structural execution risk that could materially reduce net realized revenue and slow path to self-funded growth.
Insmed News
IM8N FAQ
What was Insmed’s price range in the past 12 months?
Currently, no data Available
What is Insmed’s market cap?
Insmed’s market cap is CHF23.19B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 22, 2026 which is in 71 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 06, 2026. The company reported -CHF0.049 earnings per share for the quarter, beating the consensus estimate of -CHF0.543 by CHF0.495.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.31.
How many shares outstanding does Insmed have?
Currently, no data Available
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -CHF0.049 in its last earnings report, beating expectations of -CHF0.543. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in CH:IM8N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF162.84 (― Upside)
CHF162.84 (― Upside)
Blogger Sentiment
Bullish
CH:IM8N Sentiment 88%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF5.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.21%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
IM8N Company Deck
IM8N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and materially improved financial and clinical momentum — highlighted by BRINSUPRI’s historic launch ($309.2M Q2, raised FY guidance to $1.25B–$1.4B, peak >$7B), solid ARIKAYCE performance ($116.3M, +8% YoY) and compelling TPIP clinical data with upgraded peak potential (> $6B). Management emphasized a healthy cash position (~$1.2B) and a clear path to cash-flow positivity in 2027. Offsetting risks include higher near-term operating spend (R&D and SG&A +38% YoY), European reimbursement headwinds, milestone payments (~$50M H2 2026), and reliance on optimistic assumptions (diagnosis expansion, regulatory success, pricing). Overall, the positive commercial results, clinical readouts and funding runway substantially outweigh the noted operational and market uncertainties.View all CH:IM8N earnings summaries